Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Unichem Laboratories Ltd. Capital/Financing Update 2023

Apr 24, 2023

61109_rns_2023-04-24_2a78957f-9f28-4126-8184-cb2e486629c7.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [190 x 43] intentionally omitted <==

April 24, 2023

BSE Ltd. National Stock Exchange India Limited, Exchange Plaza, Phiroze Jeejeebhoy Towers C-1, Block-G, Dalal Street Bandra Kurla Complex, Mumbai 400 023 Bandra – (East). Mumbai-400051. Scrip Code : 506690 Scrip Code: UNICHEMLAB

Dear Sirs

  • Re: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulations”) by Unichem Laboratories Limited (“Company”).

Dr. Prakash Amrut Mody, one of the members of the promoter and promoter group of the Company (“Seller”), and IPCA Laboratories Limited (“Acquirer”) have entered into a share purchase agreement dated 24 April 2023 (“SPA”) whereby the Acquirer has agreed to purchase 2,35,01,440 fully paid-up equity shares of Rs. 2/- each, constituting 33.38 % of the fully diluted voting share capital of the Company, from the Seller, at a price of Rs. 440/- per equity share (“Proposed Transaction”). The Company is also a party to the SPA and the execution of the same was authorised by its board of directors at their meeting held on 24 April 2023.

The Proposed Transaction is subject to certain conditions precedent including receipt of approval of the Competition Commission of India under the Competition Act, 2002. Further, pursuant to execution of the SPA, the Acquirer is required to make an open offer to the public shareholders of the Company in terms of the applicable provisions of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The details required under the Regulation 30 of the SEBI LODR Regulations read with paragraph A(5) of Annexure I of SEBI Circular No. CIR/CFD/CMD/412015 dated 9 September 2015, with respect to the SPA are set out in Annexure A.

Kindly take this information on record.

Thanking you

Yours faithfully For Unichem Laboratories Limited

PRADEEP Digitally signed by PRADEEP BHANDARI BHANDARI Date: 2023.04.24 15:23:29 +05'30' Pradeep Bhandari Company Secretary and Nodal Officer Encl: a/a

==> picture [189 x 31] intentionally omitted <==

Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road Jogeshwari (West), Mumbai – 400 102, Maharashtra, India.

==> picture [190 x 43] intentionally omitted <==

ANNEXURE A

DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE
Sr.
No.
Particulars Description
1. Name(s) of parties with
whom the agreement is
entered
The share purchase agreement (“SPA”) was
executed on 24 April 2023 between Dr. Prakash
Amrut Mody (“Seller”), IPCA Laboratories Limited
(“Acquirer”) and the Unichem Laboratories Limited
(“Company”).
2. Purpose of entering into
the agreement
The SPA has been executed to record the terms of
the proposed acquisition of 2,35,01,440 equity
shares of the Company by the Acquirer from the
Seller (“Proposed Transaction”).
3. Shareholding, if any, in the
entity with whom the
agreement is executed
Nil
4. Significant terms of the
agreement (in brief) special
rights like right to appoint
directors, first right to
share subscription in case
of issuance of shares, right
to restrict any change in
capital structure etc.
1. The total purchase consideration amounts to
Rs. 1034,06,33,600.
2. The SPA is subject to certain conditions
precedent which includes receipt of approval
from the Competition Commission of India in
respect of the Proposed Transaction.
3. Pursuant to consummation of the Proposed
Transaction and subject to compliance with
the SEBI (Substantial Acquisition of Shares
and Takeovers) Regulations, 2011, the
Acquirer will become a promoter of the
Company and shall be in control of the
Company.
4. If at any time after the completion date, the
Seller is desirous of being declassified as a
“promoter” of the Company (as permitted
under SEBI LODR Regulations), the Company
and the Acquirer shall take all actions and
steps as are required to declassify the Seller
as a promoter (and to declassify the Seller’s
affiliates as ‘promotergroup’,as applicable).
5. Whether, the said parties
are
related
to
promoter/promoter
group/ group companies in
any manner. If yes, nature
**of relationship. **
Seller: Seller is a promoter of the Company.
Acquirer: The Acquire is not related to the current
promoters/ promoter group/ group companies of
the Company.

Digitally signed by PRADEEP PRADEEP BHANDARI BHANDARI Date: 2023.04.24 15:24:31 +05'30'

==> picture [189 x 31] intentionally omitted <==

Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road Jogeshwari (West), Mumbai – 400 102, Maharashtra, India.

==> picture [190 x 43] intentionally omitted <==

6. Whether the transaction
would fall within related
party transactions? If yes,
whether the same is done
at "arm's length"
No, the transaction does not involve related parties.
7. In case of issuance of
shares
to
the
parties,
details of issue price, class
of shares issued
Not applicable. No equity shares are being issued
pursuant to the SPA.
8. Any
other
disclosures
related
to
such
agreements, viz., details of
nominee on the board of
directors of the listed
entity, potential conflict of
interest arising out of such
agreements, etc.
On the completion date (as defined in the SPA), the
board of directors of the Company shall approve the
appointment of 3 (three) nominees of the Acquirer
as additional directors of the Company.
9. In case of termination or
amendment of agreement,
listed entity shall disclose
additional details to the
stock exchange(s):
(a) name of parties to the
agreement
(b)
nature
of
the
agreement (c) date of
execution
of
the
agreement
(d) details of amendment
and impact thereof or
reasons of termination and
impact thereof.
Not applicable.

PRADEEP Digitally signed by PRADEEP BHANDARI BHANDARI Date: 2023.04.24 15:24:58 +05'30'

==> picture [189 x 31] intentionally omitted <==

Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road Jogeshwari (West), Mumbai – 400 102, Maharashtra, India.